Who is sponsoring NCT04112797?

NCT04112797 is sponsored by Roxall Medicina España S.A.

What drugs are being tested in NCT04112797?

Interventions in NCT04112797: Allergovac himenoptera.

What condition does NCT04112797 study?

NCT04112797 studies Allergy to Himenoptera Venom.

Is NCT04112797 still recruiting?

NCT04112797 is currently status unknown. Last updated 16 March 2022.

Last reviewed 2022-03-16 · How we verify

NCT04112797: HIPNOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Observational Study to Evaluate the Safety of Treatment With A"LLERGOVAC® HIMENÓPTEROS" in Patients Sensitized to This Venom

Status unknown Last updated 16 March 2022

What this trial tests

trial testing Allergovac himenoptera in Allergy to Himenoptera Venom in 50 participants. Status unknown.

Timeline

23 May 2019

Primary endpoint
1 November 2023

1 November 2023

Quick facts

Lead sponsor	Roxall Medicina España S.A
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	23 May 2019
Primary completion	1 November 2023
Estimated completion	1 November 2023
Sites	8 locations across Spain

Drugs / interventions tested

Allergovac himenoptera — full drug profile →

Conditions studied

Allergy to Himenoptera Venom — all drugs for Allergy to Himenoptera Venom →

Sponsor

Roxall Medicina España S.A — full company profile →

Who can join

14 and older, any sex, with Allergy to Himenoptera Venom. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants with treatment-related adverse events as assessed by WAO classification
Time frame: During 1 year
All adverse events ocurred during the study Will be collected and clasified following the WAO recommendations. The percentages Will be exposed by number of patients and by dose administrations.

Sponsor's own description

It is a safety and tolerability study of Allergovac Himenopteros in patients sensitized to Apis mellifera, Polistes Dominula or Vespula spp. To get this aim all adverse reactions will be recorded through the study. In addition, it will be evaluated the treatment efficacy with the re-sting after a year of treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Roxall Medicina España S.A trials

Trials by the same sponsor.

NCT03821077 — Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhi · completed
NCT02844842 — Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhin · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04112797 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roxall Medicina España S.A
Last refreshed: 16 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04112797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing